Glufosfamide

Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419) . Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma[1][2][3].

Product Specifications

CAS Number

[132682-98-5]

Product Name Alternative

D 19575; Glucosylifosfamide mustard

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcl-2 Family; Caspase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GLUFOSFAMIDE.html

Purity

98.0

Solubility

H2O : 125 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@@H](O)[C@H](OP(NCCCl)(NCCCl)=O)O[C@H](CO)[C@H]1O

Molecular Formula

C10H21Cl2N2O7P

Molecular Weight

383.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Ahmed DE, et al. An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart. J Egypt Natl Canc Inst. 2021 Aug 23;33 (1) :22. |[2]Ammons WS, et al. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9 (8) :625-33. |[3]Attia RT, et al. The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ. 2016 Jun 29;4:e2168.